Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OnKure Therapeutics, Inc. (OKUR : NSDQ)

• Company Description    OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE, Calif. Number of Employees: 35

• Price / Volume Information    Yesterday's Closing Price: $2.90 Daily Weekly Monthly 20 Day Moving Average: 139,841 shares Shares Outstanding: 13.55 (millions) Market Capitalization: $39.29 (millions) Beta: 0.47 52 Week High: $9.40 52 Week Low: $1.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.27% 10.45% 12 Week -7.35% -8.84% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6707 Winchester Circle Suite 400 - Boulder,CO 80301 USA ph: 720-307-2892 fax: - daniel@lifesciadvisors.com https://onkuretherapeutics.com

• General Corporate Information    Officers Nicholas A. Saccomano - President and Chief Executive Officer Jason Leverone - Chief Financial Officer R. Michael Carruthers - Director Michael Grey - Director Valerie M. Jansen - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68277Q105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/09/26 Share - Related Items Shares Outstanding: 13.55 Most Recent Split Date: 10.00 (0.10:1) Beta: 0.47 Market Capitalization: $39.29 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.92 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.59 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.91% vs. Previous Quarter: 4.39% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -74.86 06/30/25 - -60.52 ROA 12/31/25 - - 09/30/25 - -67.92 06/30/25 - -55.43 Current Ratio 12/31/25 - - 09/30/25 - 11.45 06/30/25 - 11.13 Quick Ratio 12/31/25 - - 09/30/25 - 11.45 06/30/25 - 11.13 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 4.90 06/30/25 - 5.78 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©